SQZ News and Press, SQZ Biotechnologies Company From 04/28/22

RCM Technologies (RCMT) +25% on Q1 results. SQZ Biotechnologies (SQZ)+17% gets FDA fast track nod for its cell therapy to treat human papillomavirus positive cancers. Meta Platforms (FB) +15% on Q1 results. Atomera (ATOM) +11% on Q1 results. Blackboxstocks (...

Shares of SQZ Biotechnologies (NYSE:SQZ) jumped 19.1% to $3.30 in aftermarket trading on Wednesday, after the U.S. Food and Drug Administration (FDA) granted a Fast Track designation to the company's lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of human papillomavirus (HPV) po...

Designation Creates Potential to Bring Important New Therapy to Patients Earlier SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the U.S. Food and Drug Administration (FDA) ha...

ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Small cap stocks struggled during the first quarter as in...

SQZ ® eAPC Platform Demonstrates that mRNA-based Expression of Co-Stimulatory CD86 and Membrane-bound IL-2 and IL-12 Dramatically Increases Antigen-Specific CD8 T Cell Activity T Cell Responses Shown Across Multiple Antigens In Vitro and In Vivo Using mRNAs that Encode Infe...

SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Armon Sharei, Ph.D., Chief Executive Officer and Founder of SQZ Biotechnologies, will present at the 21st Annual Needham Virtual Healthcare Con...

Tolerizing Antigen Carriers (TACs) Shown Preclinically to Combat Autoimmunity Through Deletion of Autoreactive T Cells, Anergy and Induction of Regulatory T Cells that Facilitate Potent Bystander Suppression Demonstrated Durable Protection Against Hyperglycemia in a Type 1 Dia...

SQZ Biotechnologies (NYSE:SQZ) announced that it has been awarded a $2M SBIR Phase II grant from the National Institute of General Medical Sciences, a division of the National Institutes of Health. The two-year grant project to focus on creating dopamine-producing neurons using dire...

Project to Focus on Creating Dopamine-Producing Neurons Using Direct mRNA-based Reprogramming of Immune Cells SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has been awarded a...

SQZ Biotechnologies press release (NYSE:SQZ): FY GAAP EPS of -$2.49 beats by $0.26. Revenue of $27.1M (+29.1% Y/Y) beats by $5.22M. As of December 31, 2021, the company had cash and cash equivalents of $143.5 million and anticipates this will be sufficient to fund operating expenses and capit...